Report Thumbnail
Product Code LP09130144751SJ
Published Date 2023/6/5
LP Information
English72 PagesGlobal

Global Remicade (Infliximab) Monoclonal Antibody Market Growth 2023-2029 ‐ Pharmaceutical_LifeSciense Market


Report Thumbnail
Product Code LP09130144751SJ◆The Jun 2025 edition is also likely available. We will check with the publisher immediately.
Published Date 2023/6/5
LP Information
English 72 PagesGlobal

Global Remicade (Infliximab) Monoclonal Antibody Market Growth 2023-2029 ‐ Pharmaceutical_LifeSciense Market


Abstract

Summary

The global Remicade (Infliximab) Monoclonal Antibody market size is projected to grow from US$ 2494.5 million in 2022 to US$ 3703.9 million in 2029; it is expected to grow at a CAGR of 5.8% from 2023 to 2029.
The Remicade (Infliximab) monoclonal antibody market is driven by several factors. One of the primary drivers is the high prevalence of chronic autoimmune diseases, such as rheumatoid arthritis, Crohn's disease, and psoriasis, which require targeted immunotherapy for effective management. Remicade, as a monoclonal antibody, has demonstrated significant efficacy in treating these conditions by specifically targeting and inhibiting tumor necrosis factor-alpha (TNF-alpha), a key mediator of inflammation. Additionally, the increasing adoption of biologic therapies, including monoclonal antibodies, in clinical practice has fueled the demand for Remicade. The proven clinical efficacy, long-term safety profile, and established therapeutic outcomes have contributed to its market growth. Moreover, the expanding patient pool, coupled with the rising awareness and diagnosis rates of autoimmune diseases, has created a greater demand for targeted biologic treatments like Remicade. Furthermore, the presence of robust research and development activities aimed at developing novel monoclonal antibodies and exploring new indications for Remicade continues to drive market growth. Overall, the Remicade monoclonal antibody market is driven by the high prevalence of autoimmune diseases, increasing adoption of biologic therapies, established clinical efficacy, expanding patient pool, and ongoing research and development efforts.
Infliximab is a monoclonal anti tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis. Avsola, Flixabi, Inflectra, Remicade, Renflexis.
LPI (LP Information)' newest research report, the “Remicade (Infliximab) Monoclonal Antibody Industry Forecast” looks at past sales and reviews total world Remicade (Infliximab) Monoclonal Antibody sales in 2022, providing a comprehensive analysis by region and market sector of projected Remicade (Infliximab) Monoclonal Antibody sales for 2023 through 2029. With Remicade (Infliximab) Monoclonal Antibody sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Remicade (Infliximab) Monoclonal Antibody industry.
This Insight Report provides a comprehensive analysis of the global Remicade (Infliximab) Monoclonal Antibody landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Remicade (Infliximab) Monoclonal Antibody portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Remicade (Infliximab) Monoclonal Antibody market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Remicade (Infliximab) Monoclonal Antibody and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Remicade (Infliximab) Monoclonal Antibody.
This report presents a comprehensive overview, market shares, and growth opportunities of Remicade (Infliximab) Monoclonal Antibody market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Brand
Biosimilar
Segmentation by application
Ankylosing Spondylitis
Rheumatoid Arthritis
Crohn’s Disease
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
J & J
Pfizer
Organon
Amgen
Key Questions Addressed in this Report
What is the 10-year outlook for the global Remicade (Infliximab) Monoclonal Antibody market?
What factors are driving Remicade (Infliximab) Monoclonal Antibody market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Remicade (Infliximab) Monoclonal Antibody market opportunities vary by end market size?
How does Remicade (Infliximab) Monoclonal Antibody break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

Table of Contents

  • 1 Scope of the Report

    • 1.1 Market Introduction
    • 1.2 Years Considered
    • 1.3 Research Objectives
    • 1.4 Market Research Methodology
    • 1.5 Research Process and Data Source
    • 1.6 Economic Indicators
    • 1.7 Currency Considered
    • 1.8 Market Estimation Caveats

  • 2 Executive Summary

    • 2.1 World Market Overview
      • 2.1.1 Global Remicade (Infliximab) Monoclonal Antibody Annual Sales 2018-2029
      • 2.1.2 World Current & Future Analysis for Remicade (Infliximab) Monoclonal Antibody by Geographic Region, 2018, 2022 & 2029
      • 2.1.3 World Current & Future Analysis for Remicade (Infliximab) Monoclonal Antibody by Country/Region, 2018, 2022 & 2029
    • 2.2 Remicade (Infliximab) Monoclonal Antibody Segment by Type
      • 2.2.1 Brand
      • 2.2.2 Biosimilar
    • 2.3 Remicade (Infliximab) Monoclonal Antibody Sales by Type
      • 2.3.1 Global Remicade (Infliximab) Monoclonal Antibody Sales Market Share by Type (2018-2023)
      • 2.3.2 Global Remicade (Infliximab) Monoclonal Antibody Revenue and Market Share by Type (2018-2023)
      • 2.3.3 Global Remicade (Infliximab) Monoclonal Antibody Sale Price by Type (2018-2023)
    • 2.4 Remicade (Infliximab) Monoclonal Antibody Segment by Application
      • 2.4.1 Ankylosing Spondylitis
      • 2.4.2 Rheumatoid Arthritis
      • 2.4.3 Crohn’s Disease
      • 2.4.4 Other
    • 2.5 Remicade (Infliximab) Monoclonal Antibody Sales by Application
      • 2.5.1 Global Remicade (Infliximab) Monoclonal Antibody Sale Market Share by Application (2018-2023)
      • 2.5.2 Global Remicade (Infliximab) Monoclonal Antibody Revenue and Market Share by Application (2018-2023)
      • 2.5.3 Global Remicade (Infliximab) Monoclonal Antibody Sale Price by Application (2018-2023)

  • 3 Global Remicade (Infliximab) Monoclonal Antibody by Company

    • 3.1 Global Remicade (Infliximab) Monoclonal Antibody Breakdown Data by Company
      • 3.1.1 Global Remicade (Infliximab) Monoclonal Antibody Annual Sales by Company (2018-2023)
      • 3.1.2 Global Remicade (Infliximab) Monoclonal Antibody Sales Market Share by Company (2018-2023)
    • 3.2 Global Remicade (Infliximab) Monoclonal Antibody Annual Revenue by Company (2018-2023)
      • 3.2.1 Global Remicade (Infliximab) Monoclonal Antibody Revenue by Company (2018-2023)
      • 3.2.2 Global Remicade (Infliximab) Monoclonal Antibody Revenue Market Share by Company (2018-2023)
    • 3.3 Global Remicade (Infliximab) Monoclonal Antibody Sale Price by Company
    • 3.4 Key Manufacturers Remicade (Infliximab) Monoclonal Antibody Producing Area Distribution, Sales Area, Product Type
      • 3.4.1 Key Manufacturers Remicade (Infliximab) Monoclonal Antibody Product Location Distribution
      • 3.4.2 Players Remicade (Infliximab) Monoclonal Antibody Products Offered
    • 3.5 Market Concentration Rate Analysis
      • 3.5.1 Competition Landscape Analysis
      • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
    • 3.6 New Products and Potential Entrants
    • 3.7 Mergers & Acquisitions, Expansion

  • 4 World Historic Review for Remicade (Infliximab) Monoclonal Antibody by Geographic Region

    • 4.1 World Historic Remicade (Infliximab) Monoclonal Antibody Market Size by Geographic Region (2018-2023)
      • 4.1.1 Global Remicade (Infliximab) Monoclonal Antibody Annual Sales by Geographic Region (2018-2023)
      • 4.1.2 Global Remicade (Infliximab) Monoclonal Antibody Annual Revenue by Geographic Region (2018-2023)
    • 4.2 World Historic Remicade (Infliximab) Monoclonal Antibody Market Size by Country/Region (2018-2023)
      • 4.2.1 Global Remicade (Infliximab) Monoclonal Antibody Annual Sales by Country/Region (2018-2023)
      • 4.2.2 Global Remicade (Infliximab) Monoclonal Antibody Annual Revenue by Country/Region (2018-2023)
    • 4.3 Americas Remicade (Infliximab) Monoclonal Antibody Sales Growth
    • 4.4 APAC Remicade (Infliximab) Monoclonal Antibody Sales Growth
    • 4.5 Europe Remicade (Infliximab) Monoclonal Antibody Sales Growth
    • 4.6 Middle East & Africa Remicade (Infliximab) Monoclonal Antibody Sales Growth

  • 5 Americas

    • 5.1 Americas Remicade (Infliximab) Monoclonal Antibody Sales by Country
      • 5.1.1 Americas Remicade (Infliximab) Monoclonal Antibody Sales by Country (2018-2023)
      • 5.1.2 Americas Remicade (Infliximab) Monoclonal Antibody Revenue by Country (2018-2023)
    • 5.2 Americas Remicade (Infliximab) Monoclonal Antibody Sales by Type
    • 5.3 Americas Remicade (Infliximab) Monoclonal Antibody Sales by Application
    • 5.4 United States
    • 5.5 Canada
    • 5.6 Mexico
    • 5.7 Brazil

  • 6 APAC

    • 6.1 APAC Remicade (Infliximab) Monoclonal Antibody Sales by Region
      • 6.1.1 APAC Remicade (Infliximab) Monoclonal Antibody Sales by Region (2018-2023)
      • 6.1.2 APAC Remicade (Infliximab) Monoclonal Antibody Revenue by Region (2018-2023)
    • 6.2 APAC Remicade (Infliximab) Monoclonal Antibody Sales by Type
    • 6.3 APAC Remicade (Infliximab) Monoclonal Antibody Sales by Application
    • 6.4 China
    • 6.5 Japan
    • 6.6 South Korea
    • 6.7 Southeast Asia
    • 6.8 India
    • 6.9 Australia
    • 6.10 China Taiwan

  • 7 Europe

    • 7.1 Europe Remicade (Infliximab) Monoclonal Antibody by Country
      • 7.1.1 Europe Remicade (Infliximab) Monoclonal Antibody Sales by Country (2018-2023)
      • 7.1.2 Europe Remicade (Infliximab) Monoclonal Antibody Revenue by Country (2018-2023)
    • 7.2 Europe Remicade (Infliximab) Monoclonal Antibody Sales by Type
    • 7.3 Europe Remicade (Infliximab) Monoclonal Antibody Sales by Application
    • 7.4 Germany
    • 7.5 France
    • 7.6 UK
    • 7.7 Italy
    • 7.8 Russia

  • 8 Middle East & Africa

    • 8.1 Middle East & Africa Remicade (Infliximab) Monoclonal Antibody by Country
      • 8.1.1 Middle East & Africa Remicade (Infliximab) Monoclonal Antibody Sales by Country (2018-2023)
      • 8.1.2 Middle East & Africa Remicade (Infliximab) Monoclonal Antibody Revenue by Country (2018-2023)
    • 8.2 Middle East & Africa Remicade (Infliximab) Monoclonal Antibody Sales by Type
    • 8.3 Middle East & Africa Remicade (Infliximab) Monoclonal Antibody Sales by Application
    • 8.4 Egypt
    • 8.5 South Africa
    • 8.6 Israel
    • 8.7 Turkey
    • 8.8 GCC Countries

  • 9 Market Drivers, Challenges and Trends

    • 9.1 Market Drivers & Growth Opportunities
    • 9.2 Market Challenges & Risks
    • 9.3 Industry Trends

  • 10 Manufacturing Cost Structure Analysis

    • 10.1 Raw Material and Suppliers
    • 10.2 Manufacturing Cost Structure Analysis of Remicade (Infliximab) Monoclonal Antibody
    • 10.3 Manufacturing Process Analysis of Remicade (Infliximab) Monoclonal Antibody
    • 10.4 Industry Chain Structure of Remicade (Infliximab) Monoclonal Antibody

  • 11 Marketing, Distributors and Customer

    • 11.1 Sales Channel
      • 11.1.1 Direct Channels
      • 11.1.2 Indirect Channels
    • 11.2 Remicade (Infliximab) Monoclonal Antibody Distributors
    • 11.3 Remicade (Infliximab) Monoclonal Antibody Customer

  • 12 World Forecast Review for Remicade (Infliximab) Monoclonal Antibody by Geographic Region

    • 12.1 Global Remicade (Infliximab) Monoclonal Antibody Market Size Forecast by Region
      • 12.1.1 Global Remicade (Infliximab) Monoclonal Antibody Forecast by Region (2024-2029)
      • 12.1.2 Global Remicade (Infliximab) Monoclonal Antibody Annual Revenue Forecast by Region (2024-2029)
    • 12.2 Americas Forecast by Country
    • 12.3 APAC Forecast by Region
    • 12.4 Europe Forecast by Country
    • 12.5 Middle East & Africa Forecast by Country
    • 12.6 Global Remicade (Infliximab) Monoclonal Antibody Forecast by Type
    • 12.7 Global Remicade (Infliximab) Monoclonal Antibody Forecast by Application

  • 13 Key Players Analysis

    • 13.1 J & J
      • 13.1.1 J & J Company Information
      • 13.1.2 J & J Remicade (Infliximab) Monoclonal Antibody Product Portfolios and Specifications
      • 13.1.3 J & J Remicade (Infliximab) Monoclonal Antibody Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.1.4 J & J Main Business Overview
      • 13.1.5 J & J Latest Developments
    • 13.2 Pfizer
      • 13.2.1 Pfizer Company Information
      • 13.2.2 Pfizer Remicade (Infliximab) Monoclonal Antibody Product Portfolios and Specifications
      • 13.2.3 Pfizer Remicade (Infliximab) Monoclonal Antibody Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.2.4 Pfizer Main Business Overview
      • 13.2.5 Pfizer Latest Developments
    • 13.3 Organon
      • 13.3.1 Organon Company Information
      • 13.3.2 Organon Remicade (Infliximab) Monoclonal Antibody Product Portfolios and Specifications
      • 13.3.3 Organon Remicade (Infliximab) Monoclonal Antibody Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.3.4 Organon Main Business Overview
      • 13.3.5 Organon Latest Developments
    • 13.4 Amgen
      • 13.4.1 Amgen Company Information
      • 13.4.2 Amgen Remicade (Infliximab) Monoclonal Antibody Product Portfolios and Specifications
      • 13.4.3 Amgen Remicade (Infliximab) Monoclonal Antibody Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.4.4 Amgen Main Business Overview
      • 13.4.5 Amgen Latest Developments

  • 14 Research Findings and Conclusion

USD 3,660 or Partial Purchase
*Prices are subject to change by the publisher.
© 2026 ShareFair Inc.
Global Remicade (Infliximab) Monoclonal Antibody Market Growth 2023-2029 | Pharmaceutical_LifeSciense Market Research Report - ShareFair Markets